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2Abstract
Purpose: To investigate demographic, clinical and neuropsychological aspects of self-
harm in schizophrenia and identify which are independently predictive of and
therefore the most relevant to clinical intervention.
Subjects and methods: Eighty-seven patients with schizophrenia were interviewed
regarding substance misuse, depression, hopelessness, negative/positive symptoms
and illness insight. Neuropsychological assessment included premorbid IQ,
continuous performance test, cognitive-motor and trait impulsivity. A prospective
three-month review of medical records was also undertaken.
Results: Fifty-nine patients (68%) reported past self-harm (including attempted
suicide). Those with past self-harm, compared to those without, were significantly
more likely to report depression, hopelessness, impulsivity, a family history of self-
harm, polysubstance abuse and had higher premorbid IQ. Logistic regression revealed
that depression, higher premorbid IQ and polysubstance abuse were independently
linked to self-harm. Five participants attempted self-harm during the 3-month
prospective follow-up period. These all had a history of past self-harm and were
significantly more likely to have been depressed at the initial interview than those
who did not go on to self-harm.
Discussion and conclusions: Independent predictors of self-harm in schizophrenia are
premorbid IQ and polysubstance abuse. In addition, depression was both
independently associated with past self-harm and predictive of self-harm in the
follow-up period.
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41. Introduction
Self-harm is defined as
[35]. It therefore includes behaviours that are also described by
various other terms, such as self-poisoning, self-mutilation, parasuicide or attempted
suicide. Self-harm in schizophrenia is a major clinical and public health concern.
People with schizophrenia are about 12 to 16 times more likely to die from suicide
than the general population [14, 29]. Approximately 11% of patients with
schizophrenia self-harm between the onset of psychosis and first presentation to
mental health services [18]. The presence of self-harm among people with
schizophrenia is a clinically significant risk factor for later completed suicide [36, 42].
Exact figures on the lifetime prevalence of self-harm associated with schizophrenia
are difficult to ascertain because much of the evidence is based upon studies of
completed suicides. However, one study followed a group of young schizophrenia
patients over 14-17 years and reported that overall self-harm prevalence during the
period was 48% [37]. One meta-analytic study suggested that the risk of death by
suicide amongst people with schizophrenia is about 5% [39]. Self-harm therefore
appears to be a significant aspect of schizophrenia.
Clinical features associated with schizophrenia patients who self-harm, compared to
similar patients who do not, include suicidal ideation, previous self-harm, past
depression, substance abuse, and past psychiatric admissions [20]. Clinical predictors
of completed suicide include previous self-harm, substance abuse, preserved illness
insight, depression, delusions and hallucinations [22, 23]. However, in one large UK
regression study of demographics and symptoms within the first year of psychosis
5onset, no specific symptom profiles were associated with later completed suicide,
though a cumulative effect of symptoms was [13].
Compared to those who do not self-harm, people with schizophrenia who self-harm
may have higher cognitive functioning. In a study comparing those with and those
without a history of suicide attempts among patients with either schizophrenia or
schizoaffective disorder, better attention and executive functions were observed in the
suicide group [33]. Better insight into their illness has also been demonstrated in
groups of schizophrenia patients who attempt suicide, when compared to patients that
do not [45]. They may also be more impulsive [24]. Other factors associated with an
increased risk of self-harm include being male [18], and being relatively well
educated [42].
We wished to ascertain the relative importance of these multiple associations. We
aimed to identify the contribution of several key factors associated with past self-harm
in schizophrenia and calculate which factors are independently linked to the
occurrence of self-harming behaviour. In addition we followed-up participants for
three months to investigate which factors are predictive of future self-harm.
62. Subjects and methods
2.1 Subjects
We recruited 87 patients meeting DSM-IV criteria for schizophrenia from the
community and from hospital wards in the South Yorkshire region of the UK. The
patients' diagnoses of schizophrenia had been determined by their clinical teams. The
diagnoses were verified by the interviewing psychiatrist who had access to the
patients full notes. This sample size had the power to detect, using a Chi2-test, a
medium-sized difference with one degree of freedom ( =0.05; =0.80) [10]. The final
sample contained 78 male and 9 female patients and the mean duration of illness was
16.9 years (SD = 11.7). The sample had a mean of 11.4 years of education (SD = 2.4).
2.2 Assessments
The patients were interviewed individually by one of three psychiatrists.
Demographic and clinical information was recorded, including duration of illness,
family history of mental illness and history of substance misuse. Individual past
history of self-harm was recorded with the Deliberate Self-harm Inventory, a schedule
that records a range of common self-harmful behaviours that the individual does not
class as suicidal [16]. Our enquiries included an open ended item to record any forms
of self-harm not featured in the main items of the inventory. In addition, any history
of events that the patient considered to be suicide attempts were elicited and recorded
using a published schedule [47]. This data was used to classify patients into those
with, or without, past histories of self-harm based on a standard definition [21].
The clinical researcher then administered the Calgary Depression Scale [1]. Insight
into illness was assessed using the Schedule for the Assessment of Insight [11] and a
7general clinical assessment with the Global Assessment of Functioning Scale from the
DSM-IV-TR [4]. The patients completed the self-report Barratt Impulsiveness Scale-
11 [40] and Beck Hopelessness Scale [8]. The Scale for the Assessment of Negative
Symptoms (SANS) [5] and the Scale for the Assessment of Positive Symptoms
(SAPS) [6] were administered.
All the cognitive assessments were administered by a neuropsychologist following the
clinical interview. Premorbid IQ was estimated with the National Adult Reading Test
[34]. The Trail Making Test [41] was used to assess frontal executive function.
Sustained attention and vigilance were assessed with a computerised auditory
Continuous Performance Test [28]. Cognitive-motor impulsivity was assessed with a
computerised visual Go/No-Go reaction time task (240 Go stimuli and 60 No-Go
stimuli).
2.3 Procedure
The research protocol was approved by both the South Sheffield and South Yorkshire
Research Ethics Committees. All patients gave informed consent and were
interviewed in a private room. The entire procedure took approximately two and a
half hours; breaks were given and the sessions were spread over two or more
occasions if the patient became fatigued. A payment of £10 (approximately US$16)
was given to each patient.
2.4 Data analysis
The deliberate self-harm inventory or any behaviour that appeared to be a past suicide
attempt revealed in the clinical interview was used to classify patients into those with,
8or without, past histories of self-harm according to a standard definition [21]. For the
continuous variables, the normality of the distributions was analysed using
Kolmogorov-Smirnov one-sample tests. The two groups were compared using one-
way Analysis of Variance (ANOVA), or using Mann-Witney tests if non-normally
distributed. Scores on the Calgary Depression Scale were used to categorise
individuals as probable current clinical depression based on the standard cut-off score
of >6 [1]. Substance misuse history was summarised using two variables, whether or
not the patient reported ever having been an injector of illicit substances (as a measure
ever abused (as a measure of polysubstance abuse).
For the Trail Making Test the time taken to complete trails B minus A was used
giving a statistic that controls for non-specific motor slowness. For the continuous
performance test, a signal detection analysis was performed on the accuracy of
responses to calculate d , a measure of sensitivity. On the Go/No-Go task, the
proportions of commission errors were calculated. This gives a measure of cognitive-
motor impulsivity, controlled for general level of performance.
Categorical data were compared using Chi2 tests (with continuity correction) with 2x2
tables for group membership and binary categorical variables. All tests were two-
tailed, and criterion level of p was .05. Further analyses involved regression of all
the variables that differed significantly between the groups with p 0.1. Independent
variables were entered stepwise, using a probability of F to enter at 0.05 and a
probability of F to remove at 0.10. The dependent variable was the presence or
absence of past self-harm.
92.5 Prospective follow-up
All 87 participants were followed-up via searches of their on-line medical records.
Data were collected on acts of self-harm that had required medical attention in the
three month period starting when they participated in the last research interview. This
involved all available clinical correspondence in the three month period and
-
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3. Results
Fifty-nine patients (68%) reported some form of past self-harm. Patients were dived
into those with and those without past self-harm and the results are summarised in
Table 1. The group that reported lifetime self-harm reported current higher levels of
hopelessness, were more likely to be depressed than those without a history of self-
harm, and were more likely to report a family history of self-harm. The self-harm
group reported significantly higher levels of lifetime polysubstance abuse, trait
impulsivity and had significantly higher estimated premorbid IQs than the group
without a history of self-harm. There were no significant differences between the
groups on the other neuropsychological measures or SANS/SAPS scores, global
functioning or illness insight scores. The self-harm group, compared to the no self-
harm group, were significantly more likely to have a family history of self-harm.
However, there were no significant differences between groups for any of the other
demographical variables collected (i.e. age, sex or education).
TABLE 1 About here
The data presented in Table 1 were used to indentify candidate variables for the
regression analyses. The percentage of patients who had been intravenous drug users
was not entered because despite being statistically significant at p 0.1, the data
overlapped with the polysubstance abuse variable, which was selected as it had a
lower p value. The variables entered into the regression were therefore: family history
of self-harm, depression, hopelessness, polysubstance abuse, estimated premorbid IQ,
cognitive-motor impulsivity and trait impulsivity.
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The results are shown in Table 2. Five variables were included in the final model,
these were estimated premorbid IQ, depression, polysubstance abuse, family history
of self-harm and trait impulsivity. Of these five, three were independently associated
with the occurrence of past self-harm; current depression (p=0.019), estimated
premorbid IQ (p=0.011) and lifetime polysubstance abuse (p=0.017). People with
current depression were more likely to have previously self-harmed. In addition, each
increment in the estimated premorbid IQ and in the number of substances used was
associated with an increased likelihood of self-harm.
TABLE 2 about here
SANS and SAPS total scores were not found to be related to self-harm, however, it is
possible that specific symptom profiles would be. To explore this, we performed an
additional logistic regression analysis entering all of the SANS and SAPS subscale
scores as covariates and group membership as the dependent variable. None of the
SANS or SAPS subscale scores were found to be significantly related to self-harm.
3.1 Prospective follow-up
Acts of self-harm were recorded in the records of 5 of the 87 original participants in
the 3-month follow-up period. This indicates a 3-month incidence of approximately
5.7%. All 5 cases were classified at the original clinical interview as members of the
group of 59 individuals with past histories of self-harm. However, due to the low
power, this association is not statistically sign p=.173).
12
Those five who were known to have self-harmed in the follow-up period were
compared to the 82 who were not known to have self-harmed. For this we used all the
key variables identified in the retrospective analysis described above (i.e. those
independent variables with p 0.1 in Table 1). The only factor with a statistically
test, p=.046). Four of the five patients (80%) who self-harmed during the follow-up
period had been categorised as depressed at the original research interview. This
compares to those who were not known to have self-harmed in the follow-up period,
of whom only 26/82 (32%) were categorised as depressed at the original research
interview.
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4. Discussion
We found a high rate of self-harm in our sample of people with schizophrenia. Using
a wide definition [21] that includes any self-poisoning or non-fatal behaviour intended
to cause self-harm, we found that over two thirds of our sample reported such past
behaviour. It has been estimated that the prevalence of self-harm in nonclinical
populations is between about 4% [26] and 11% [21]. Our finding of a prevalence of
68% highlights the seriousness of this medically dangerous aspect of schizophrenia.
Patients with self-harm were more likely to report a family history of self-harm.
Furthermore, those in our sample with past self-harm were more likely to be
depressed than those with no history of self-harm. This in itself is not surprising; self-
harm has been clearly linked to negative mood, including depression in general [15],
and to the occurrence of self-harm in schizophrenia, including completed suicide [9,
31]. In addition, reported levels of hopelessness were also raised in those of our
sample who had self-harm histories. Again, this is not surprising as hopelessness
underlies a range of psychiatric disorders and be a direct risk for self-harm [8],
particularly in those who suffer from depression [8] and has been linked to suicide
among people with schizophrenia [46].
Neither positive nor negative symptoms were linked to self-harm. This seems to
imply that self-harm occurs relatively independently of the core features of
schizophrenia. However, self-harm was found to be closely linked to depressive
symptomology. It may be that depression occurs in schizophrenia independently of
the classical positive and negative symptom profiles [27]. If this is correct, then the
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prevention of self-harm in schizophrenia will not be well addressed by treating only
the core symptoms of the disease.
In the literature on suicide by psychiatric patients in general, personality disorder is a
significant risk factor [30]. One study of self-harm by patients presenting to a general
hospital found that 46% had personality disorders, 92% had psychiatric disorders and
comorbidity of the two was 44% [19]. Indeed, DSM-IV axis I and II comorbidity
conveys a significant risk of suicide, and overall the presence of a DSM-IV
personality disorder conveys a seven fold risk of suicide [44]. This is less of an issue
in individuals with schizophrenia, in which suicide is not as closely linked to either
personality or psychiatric comorbidity [31]. For the sake of brevity Axis-II disorders
were not studied in this research. Nevertheless, our observed high rate of self-harm
indicates that personality disorder may be a factor and perhaps should be considered
in future research.
Our findings partially support the past observations that individuals with
schizophrenia and self-harm history have relatively preserved neuropsychological
functions [33]. In our study self-harm was associated with relatively higher premorbid
IQ, but not with other measures of cognitive function. However, other researchers
have failed to find such associations. In one study, suicide attempters with
schizophrenia did not differ significantly from non-attempters on a range of
neurocognitive measures, and in fact were significantly worse at inhibitory control
[7].
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It is of particular interest that high premorbid IQ may be linked to self-harm in
schizophrenia, as the converse is found in other samples selected solely on the
occurrence of self-harm. In such groups, it is low premorbid cognitive function that is
usually associated with self-harm. For example, studies of military conscripts in
Denmark and Sweden have shown that low cognitive function at enlistment is
predictive of later life suicide and self-harm [25, 38]. Furthermore, an Australian
study has shown that lower actual IQ at age 14 predicts suicide thoughts, plans and
attempts at age 21 [3].
We suggest that the reason premorbid IQ is linked to self-harm in schizophrenia
maybe that those with high IQ premorbidly experience a greater sense of personal
decline. There may be a greater mismatch between the earlier life aspirations and
current lifestyles in those patients with higher premorbid IQ, which could drive self-
harm behaviour. Support for this comes from the finding that completed suicide is
associated with higher educational achievement of people with psychiatric illness in
general [2, 30] as well as those with schizophrenia [42]. Furthermore, illness insight is
itself closely linked to preserved cognitive function in schizophrenia [12]. Higher
premorbid IQ may therefore have a protective effect on awareness of impairment,
which is also linked to self-harm [45].
The result of the regression analysis was the identification of three main factors; these
were the presence of current depression, lifetime polysubstance abuse and relatively
high premorbid IQ. While the Odds Ratio for premorbid IQ is close to 1, each unit
increase in IQ score is associated with a 6% increase in the risk of self-harm. IQ is a
scale measurement with an estimated population mean set at 100, so each increment is
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relatively small; however, the increased risk of self-harm across a wider range of
scores (e.g., a ten-point difference in IQ) is correspondingly higher (e.g., 60%).
The current design is primarily a cross-sectional study, and only included a minor
longitudinal aspect. This is a limitation. In particular, it should be noted that those
who were eligible to be included in the study may have been different to those who
are no longer in the local population of patients. Individuals in the catchment area
who had completed suicide, for example, would not feature in the data set. Indeed,
suicide is most common shortly after first contact with psychiatric services, both for
psychiatric patients in general [36], and for those with schizophrenia [39]. This may
limit the generalisability of our findings. In contrast, a common criticism of medical
research is that it often does not present results that are directly of use to those
working with patients. This is often caused by reporting on samples that are not
representative of the patients seen day-to-day [43]. However, cross sectional studies
such as this do in fact present a relatively realistic sample of the patients which will be
seen in the clinic. An example of this is that the male:female ratio in our sample was
9:1, despite the global incidence rate of schizophrenia amongst males and females
being around 1.4:1 [32]. However, remission of schizophrenia is much more common
in women [17], consequently, there are in fact far more male than female
schizophrenic individuals in contact with psychiatric services.
All patients were followed up by analysis of their medical records for three months.
There were five cases of self-harm recorded as requiring medical attention in the
follow-up period. Past history of self-harm was 100% accurate at predicting these
events, highlighting the clinical significance that should be placed on self-harm
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history in people with schizophrenia. We also found that depression was a statistically
significant predictor of future self-harm.
The size of the group studied was based on a sample size estimation for the
retrospective part of the research. The prospective follow-up found self-harm in only
5 of the original 87 group members. This therefore limits interpretation of the results.
Nevertheless, the analysis based on retrospective allocation to groups was sufficiently
powered and was able to identify lifetime polysubstance abuse, premorbid IQ and
current depression as independent risk factors for the occurrence of self-harm.
An alternative explanation for our findings of self-harm being particularly linked to
depression could be made. It could be argued that those individuals who were
depressed were more likely to recall past self-harm than those who were not
depressed, irrespective of the actual true past history of self-harm. In this case
depressive cognitions would distort the allocation to either the past self-harm or no
self-harm groups. A related issue is that higher premorbid IQ could be linked to better
recall of past self-harm (irrespective of true self-harm history). Again, this could
distort the statistical allocation of individuals to groups. Thus, our findings should be
interpreted cautiously as it is a mainly a retrospective design, susceptible to sampling
bias. Nevertheless, our prospective follow-up data show that current depression
predicts future self-harm, which accords with previous prospective research showing
that depression strongly predicts later suicide plans and attempts [9].
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5. Conclusion
This study indicates the clinical importance of three factors identified as being
independently linked to self-harm: lifetime polysubstance abuse, high premorbid IQ
and current depression. Of these, depression is of particular interest for psychiatrists
working with patients as it was also predictive of future self-harm. Self-harm among
patients with schizophrenia should be considered as an ongoing high risk rather than
being exceptional. Clinicians treating individuals with schizophrenia should be aware
of the signs that are significantly associated with risk of self-harm. An individual
history of polysubstance abuse and high premorbid cognitive function imply that
these patients are at increased risk of self-harm. In addition, depressive symptoms are
a clear sign of self-harm risk and our data suggest that they are more indicative of risk
than the core symptoms of the disease. It would be advisable therefore that those
professionals who assess risk and treat patients with schizophrenia concentrate on the
factors that we have identified, in particular the mood state of patients.
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SANS 8.6 () 8.4 () F=.05, p=.81
SAPS 6.0 (2.9) 5.5 (3.4) Z=-.84, p=.40
SAI 8.1 (3.5) 7.4 (4.0) F=.56, p=.46
CDS 27 (46%) 3 (11%) 2=8.83, p<.01
BHS 10.4 (5.6) 6.3 (4.3) F=12.03, p<.01
Injected drugs 12 (20%) 1 (4%) 2=2.9, p=.08
Polysubstance 3.4 (2.9) 1.6 (2.1) Z=-2.89, p<.01
Neuropsychological
NART IQ 99.5 (15.5) 90.0 (13.0) F=7.34, p<.01
TMT 115.6 (111.2) 185.2 (192.2) Z=-1.65, p=.10
3.7 (1.1) 3.5 (1.4) F=.65, p=.42
Go/No-Go 40.0 (21.1) 31.5 (19.5) F=2.92, p=.09
Table 1
BIS-11 77.4 (11.6) 70.1 (10.7) F=7.97, p<.01
For the past self-harm group, n=59, for the no self-harm group, n=28. Age, education and
duration of illness are given in years. GAFS=Global Assessment of Function Scale,
SANS=Scale for the Assessment of Negative Symptoms, SAPS=Scale for the Assessment of
Positive Symptoms, SAI=Schedule for the Assessment of Insight, CDS=Calgary Depression
Scale, BHS=Beck Hopelessness Scale. Polysubstance is the total number of classes of illicit
drugs ever used. TMT=Trail Making Test, trails B-A in seconds is shown. CPT=Continuous
-Go
task the proportion of all errors that were commissions is shown. BIS-11=Barratt
Impulsiveness Scale. For continuous data the mean total score + (SD) is shown, with
ANOVA F values if normally distributed and Mann-Whitney Z scores if not. For the nominal
- -harm, CDS positive for depression, ever
injected drugs), the actual number and percentage positive for the feature is given with the
continuity correction of the Chi2 statistic.
Table 2. Results of the stepwise logistic regression analyses to identify predictors of previous
self-harm
Variables included in
final model (reference
category)
Self-harm No Self-harm Odds ratio (95%
Confidence
Interval)
p-value
Estimated Premorbid
IQ
99.5 (15.5) 90.0 (13.0) 1.06 (1.01,1.10) 0.011
Depressed (No) 27 (46%) 3 (11%) 7.04 (1.37,36.20) 0.019
Polysubstance abuse 3.4 (2.9) 1.6 (2.1) 1.40 (1.06,1.86) 0.017
Family history of self-
harm (No)
21 (36%) 3 (11%) 3.83 (0.75,19.69) 0.108
Trait Impulsivity 77.4 (11.6) 70.1 (10.7) 1.06 (1.00,1.13) 0.065
For category variables, the actual number in the sample (+%) is shown. For continuous
variables the mean (+SD) is given.
Table 2
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